AU2005311709B2 - Compositions and methods for treating neoplastic diseases - Google Patents

Compositions and methods for treating neoplastic diseases Download PDF

Info

Publication number
AU2005311709B2
AU2005311709B2 AU2005311709A AU2005311709A AU2005311709B2 AU 2005311709 B2 AU2005311709 B2 AU 2005311709B2 AU 2005311709 A AU2005311709 A AU 2005311709A AU 2005311709 A AU2005311709 A AU 2005311709A AU 2005311709 B2 AU2005311709 B2 AU 2005311709B2
Authority
AU
Australia
Prior art keywords
cancer
compound
formula
cells
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005311709A
Other languages
English (en)
Other versions
AU2005311709A1 (en
Inventor
Kenneth C. Anderson
Dharminder Chauhan
Michael A. Palladino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Research and Development I ULC
Dana Farber Cancer Institute Inc
Original Assignee
Triphase Research and Development I Corp
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triphase Research and Development I Corp, Dana Farber Cancer Institute Inc filed Critical Triphase Research and Development I Corp
Publication of AU2005311709A1 publication Critical patent/AU2005311709A1/en
Application granted granted Critical
Publication of AU2005311709B2 publication Critical patent/AU2005311709B2/en
Assigned to DANA-FARBER CANCER INSTITUTE, INC. reassignment DANA-FARBER CANCER INSTITUTE, INC. Request to Amend Deed and Register Assignors: DANA FARBER CANCER INSTITUTE
Assigned to DANA-FARBER CANCER INSTITUTE, INC., TRIPHASE RESEARCH AND DEVELOPMENT I CORP reassignment DANA-FARBER CANCER INSTITUTE, INC. Request to Amend Deed and Register Assignors: DANA-FARBER CANCER INSTITUTE, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2005311709A 2004-12-03 2005-12-02 Compositions and methods for treating neoplastic diseases Expired AU2005311709B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63316104P 2004-12-03 2004-12-03
US60/633,161 2004-12-03
PCT/US2005/043668 WO2006060676A1 (en) 2004-12-03 2005-12-02 Compositions and methods for treating neoplastic diseases

Publications (2)

Publication Number Publication Date
AU2005311709A1 AU2005311709A1 (en) 2006-06-08
AU2005311709B2 true AU2005311709B2 (en) 2011-07-28

Family

ID=36118298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005311709A Expired AU2005311709B2 (en) 2004-12-03 2005-12-02 Compositions and methods for treating neoplastic diseases

Country Status (17)

Country Link
US (5) US20070225350A1 (enExample)
EP (1) EP1830838B1 (enExample)
JP (3) JP5676071B2 (enExample)
KR (1) KR101282191B1 (enExample)
CN (2) CN103230394B (enExample)
AU (1) AU2005311709B2 (enExample)
BR (1) BRPI0517135B1 (enExample)
CA (1) CA2588923C (enExample)
DK (1) DK1830838T3 (enExample)
ES (1) ES2396762T3 (enExample)
IL (3) IL183506A (enExample)
MX (1) MX2007006526A (enExample)
NZ (1) NZ555439A (enExample)
PL (1) PL1830838T3 (enExample)
SG (1) SG157365A1 (enExample)
WO (1) WO2006060676A1 (enExample)
ZA (1) ZA200704402B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CA2532066C (en) * 2003-06-20 2015-07-28 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CN1823070A (zh) * 2003-06-20 2006-08-23 加利福尼亚大学董事会 盐孢菌酰胺及其使用方法
MXPA06012421A (es) * 2004-04-30 2007-01-31 Nereus Pharmaceuticals Inc Compuestos de heterociclicos y metodos para utilizar los mismos.
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
ES2396762T3 (es) 2004-12-03 2013-02-26 Dana-Farber Cancer Institute, Inc. Composiciones y métodos para tratar enfermedades neoplásicas
MX2007006523A (es) * 2004-12-03 2007-09-11 Nereus Pharmaceuticals Inc Metodos para utilizar compuestos heterociclicos [3.2.0] y sus analogos.
EP1861126A4 (en) 2005-03-22 2009-11-18 Harvard College TREATMENT OF PROTEIN REMOVAL TROUBLES
WO2007056335A2 (en) * 2005-11-04 2007-05-18 The Regents Of The University Of California Methods of sensitizing cancer to therapy-induced cytotoxicity
CA2642288C (en) 2006-02-14 2014-10-07 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
CA2648317A1 (en) 2006-04-06 2007-10-18 Nereus Pharmaceuticals, Inc. Total synthesis of salinosporamide a and analogs thereof
EP2019674B1 (en) 2006-05-03 2016-11-23 The President and Fellows of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008124699A1 (en) * 2007-04-06 2008-10-16 Nereus Pharmaceuticals, Inc. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
BRPI0909661A2 (pt) 2008-03-07 2015-08-11 Nereus Pharmaceuticals Inc Composto e métodos de síntese química e de formação ou preparação de compostos
WO2009140287A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
EP2296654A4 (en) * 2008-06-06 2012-04-18 Univ Health Network 8-HYDROXYCHINOLINE DERIVATIVES FOR THE TREATMENT OF CRUISING HEMATOLOGICAL DISEASES
CN102164888B (zh) 2008-07-23 2015-06-03 哈佛大学校长及研究员协会 脱乙酰酶抑制剂和其用途
EP2318830A4 (en) * 2008-08-13 2011-09-07 George Mason Intellectual Prop THERAPEUTIC EX-VIVO SCREENING OF LIVING BONE MARROW CELLS ON MULTIPLE MYELOME
US20110319427A1 (en) * 2009-03-05 2011-12-29 University Health Network Use of 5ahq and bortezomib for the treatment of hematological diseases
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US20130173294A1 (en) * 2011-12-30 2013-07-04 Elwha LLC, a limited liability company of the State of Delaware Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
US20150299803A1 (en) * 2012-11-05 2015-10-22 Pronai Therapeutics, Inc. Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
US20180325854A1 (en) * 2015-11-06 2018-11-15 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
US10703760B2 (en) 2016-08-19 2020-07-07 Celgene International Ii Sàrl Morphic forms of marizomib and uses thereof
US11141389B2 (en) 2017-01-31 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University Agents that inhibit NGLY1 and methods of use thereof
JP7498475B2 (ja) * 2020-01-31 2024-06-12 株式会社セラバイオファーマ 多発性骨髄腫の治療剤
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138196A1 (en) * 2002-06-24 2004-07-15 William Fenical Salinosporamides and methods for use thereof
AU2005283141A1 (en) * 2004-04-30 2006-03-16 Nereus Pharmaceuticals, Inc. (3.2.0) heterocyclic compounds and methods of using the same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
ATE274347T1 (de) 1992-11-27 2004-09-15 Mayne Pharma Usa Inc Stabile injizierbare paclitaxel lösung
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
UA39962C2 (uk) 1993-10-01 2001-07-16 Сінтекс ( С.Ш.А. ) Інк. Фармацевтична композиція, яка містить мофетил мікофеноляту, для орального введення ( варіанти ) та спосіб її одержання ( варіанти )
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6838477B2 (en) 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
AU741802B2 (en) 1997-02-15 2001-12-13 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of NF-kappaB
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AU729000B2 (en) 1997-08-04 2001-01-25 Nihon Nohyaku Co., Ltd. Aryloxyaniline derivatives
IL134538A (en) 1997-08-15 2005-11-20 Millennium Pharm Inc Lactacystin derivatives and pharmaceutical compositions containing the same
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
CA2304622A1 (en) 1997-09-25 1999-04-01 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases
US20010051654A1 (en) 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
WO1999026614A1 (en) 1997-11-21 1999-06-03 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
WO1999050245A1 (en) 1998-03-26 1999-10-07 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO2000023614A1 (en) 1998-10-20 2000-04-27 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020049157A1 (en) 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
PT1326632E (pt) 2000-10-12 2007-01-31 Viromics Gmbh Tratamento para o tratamento de infecções por vírus da hepatite
JP4395549B2 (ja) 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
DE10316735A1 (de) 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CA2504933C (en) 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
CN1845925B (zh) 2003-02-14 2010-11-03 赢泰医药科技发展有限公司 取代的杂环化合物
CN1823070A (zh) 2003-06-20 2006-08-23 加利福尼亚大学董事会 盐孢菌酰胺及其使用方法
CA2532066C (en) * 2003-06-20 2015-07-28 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
WO2005094423A2 (en) 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
US7371875B2 (en) 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7183417B2 (en) 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US20060264495A1 (en) 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
KR20070041742A (ko) 2004-07-12 2007-04-19 바이엘 크롭사이언스 아게 살진균제 및 살충제로서의 치환된 2-피롤리돈 유도체
WO2006060609A1 (en) 2004-12-03 2006-06-08 Honeywell International Inc. Gas jet control for inertial measurement unit
WO2006060819A2 (en) 2004-12-03 2006-06-08 The Regents Of The University Of California Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
MX2007006523A (es) * 2004-12-03 2007-09-11 Nereus Pharmaceuticals Inc Metodos para utilizar compuestos heterociclicos [3.2.0] y sus analogos.
ES2396762T3 (es) 2004-12-03 2013-02-26 Dana-Farber Cancer Institute, Inc. Composiciones y métodos para tratar enfermedades neoplásicas
WO2006118973A2 (en) 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US20060287520A1 (en) 2005-05-16 2006-12-21 Danishefsky Samuel J Synthesis of salinosporamide A and analogues thereof
WO2007021897A1 (en) 2005-08-10 2007-02-22 President And Fellows Of Harvard College Analogs of salinosporamide a
WO2007030662A1 (en) 2005-09-09 2007-03-15 Nereus Pharmaceuticals, Inc. Biosynthesis of salinosporamide a and its analogs
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
WO2007056335A2 (en) 2005-11-04 2007-05-18 The Regents Of The University Of California Methods of sensitizing cancer to therapy-induced cytotoxicity
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
CA2648317A1 (en) 2006-04-06 2007-10-18 Nereus Pharmaceuticals, Inc. Total synthesis of salinosporamide a and analogs thereof
WO2007130404A1 (en) 2006-05-03 2007-11-15 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US8088923B2 (en) 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
US20080280968A1 (en) 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
BRPI0909661A2 (pt) 2008-03-07 2015-08-11 Nereus Pharmaceuticals Inc Composto e métodos de síntese química e de formação ou preparação de compostos
WO2009140287A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
US8772724B2 (en) 2011-01-05 2014-07-08 Intel-Ge Care Innovations Llc Low power, inexpensive velocity detection using a PIR array

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138196A1 (en) * 2002-06-24 2004-07-15 William Fenical Salinosporamides and methods for use thereof
AU2005283141A1 (en) * 2004-04-30 2006-03-16 Nereus Pharmaceuticals, Inc. (3.2.0) heterocyclic compounds and methods of using the same

Also Published As

Publication number Publication date
JP2015028089A (ja) 2015-02-12
SG157365A1 (en) 2009-12-29
AU2005311709A1 (en) 2006-06-08
KR101282191B1 (ko) 2013-07-08
ES2396762T3 (es) 2013-02-26
EP1830838B1 (en) 2012-10-03
PL1830838T3 (pl) 2013-07-31
ZA200704402B (en) 2008-07-30
WO2006060676A1 (en) 2006-06-08
EP1830838A1 (en) 2007-09-12
US8722724B2 (en) 2014-05-13
CN101155582B (zh) 2013-04-24
IL183506A0 (en) 2007-10-31
IL236426B (en) 2019-11-28
CN101155582A (zh) 2008-04-02
JP5676071B2 (ja) 2015-02-25
IL241756A0 (en) 2015-11-30
US20140349965A1 (en) 2014-11-27
MX2007006526A (es) 2007-09-19
BRPI0517135A (pt) 2008-09-30
KR20080003306A (ko) 2008-01-07
JP5837469B2 (ja) 2015-12-24
CN103230394B (zh) 2016-04-20
CA2588923A1 (en) 2006-06-08
US20230210817A1 (en) 2023-07-06
IL236426A0 (en) 2015-02-26
US20090036390A1 (en) 2009-02-05
BRPI0517135B1 (pt) 2022-04-19
CN103230394A (zh) 2013-08-07
JP2008521928A (ja) 2008-06-26
US20200206190A1 (en) 2020-07-02
HK1113462A1 (en) 2008-10-03
JP5963830B2 (ja) 2016-08-03
US10610517B2 (en) 2020-04-07
CA2588923C (en) 2015-02-03
US20070225350A1 (en) 2007-09-27
JP2012236862A (ja) 2012-12-06
IL183506A (en) 2015-10-29
NZ555439A (en) 2010-12-24
DK1830838T3 (da) 2013-01-21

Similar Documents

Publication Publication Date Title
US20230210817A1 (en) Compositions and methods for treating neoplastic diseases
Chauhan et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
EP2796134B1 (en) Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
KR102358632B1 (ko) 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
TWI280880B (en) Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances
CN112972684B (zh) Iap抑制剂与parp或mek抑制剂或其他化学治疗剂的组合
HK1113462B (en) Compositions and methods for treating neoplastic diseases
WO2023168491A1 (en) Treatment of clear cell renal cell carcinoma
CN110538172B (zh) 铁死亡抑制剂在制备治疗金诺芬肝毒性的药物中的应用
TWI827310B (zh) 異硫氰酸酯結構修飾化合物於預防或治療肝臟疾病之用途
HK1202436B (en) Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
AU2016232775A1 (en) Compositions and methods for treating hepatocellular carcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ: ANDERSON, KENNETH C, CHAUHAN, DHARMINDER AND PALLADINO, MICHAEL A. .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ANDERSON, KENNETH C.; CHAUHAN, DHARMINDER AND PALLADINO, MICHAEL A.